Dynavax Technologies Corporation

Dynavax is collaborating with China's Clover Biopharmaceuticals on a vaccine that showed 100% efficacy against severe COVID-19 and hospitalizations.

Sofi, Stitch Fix, General Mills, Marin Software and Dynavax are five top stock gainers for Wednesday.

Jim Cramer has your game plan for next week, and it includes a warning about potential volatility.

Five must reads from Jim Cramer, Jim "Rev Shark" DePorre, and the team at Real Money/Real Money Pro!

Stocks trading higher Friday include VBI Vaccines, Moderna, Novavax, Dynavax Technologies, and Quidel.

Biotech Gilead discussing voluntary licenses of remdesivir for production in Europe, Asia and developing world.

Nearly all patients treated with Gilead antiviral drug in Chicago study were discharged within a week.

GV-backed Arcus said to be in initial discussions to sell stake.

Jim Cramer weighs in on Starbucks, Square, Alibaba, ArcelorMittal, Dynavax Technologies, Aimmune Therapeutics, Clearway Energy and more.

We may be so worried about the state of the global economy that we're missing some great opportunities, Jim Cramer says.

Jim Cramer takes a closer look at Children's Place, Abiomed, Barrick Gold, Dynavax Technologies, Zebra Technologies, Chesapeake Energy.

Jim Cramer says this market is all about being opportunistic, about being willing to fight the tide.

Jim Cramer spotlights Twilio, Apache, Tellurian, Atara Biotherapeutics, Amarin, Dynavax Technologies

Jim Cramer says this is a market that triumphs over the gloom by simply taking stock of the good and running with it. He's got your game plan for next week.

Jim Cramer says investors should step away from these near-term shenanigans and focus on the fundamentals.

Jim Cramer is bullish on Chevron, Universal Display, Dynavax Technologies, and Schlumberger.

The Dow ends July with a bang.

Stocks are mixed.

Stocks are mixed.

How can we find reasonably priced stocks right now? By staying off the beaten path. Let me explain.

Here are some intriguing biotech names I am adding exposure to after the recent pullback in the sector.

Revisiting three attractive biotech companies that reported solid Q3 results last week.

These small-cap names could see a tailwind once tax-loss selling abates.

I'm making incremental moves in a complicated environment.

I am starting to build positions via covered call orders in myriad names in the space.

Here's an attractive way to start accumulating a position in this name, which should do okay once sentiment turns around.

This mid-cap biotech is ideal for a 'rinse, wash and repeat' trade.

Both names were the recipients of positive news that bolsters their investment cases.

This week I took new positions in two small-cap names and added to holdings in two others.

I'm eyeing these small cap names for 2024; and here's why I'm still skeptical on a soft landing.

The S&P Biotech fund is down nearly 60% from its highs at the start of 2021 and many names like UniQure and AbCellera Biologics are selling for far less than the net cash on their balance sheets.

This vaccine developer just released strong earnings and here's how I'm using an options play to add to the name.

The price for credit is becoming more onerous, and, at some point, a significant crunch could develop. Don't get caught by surprise.

There are reasons besides their cash positions to think these companies could see their stocks improve going forward.

They've all reported solid fourth-quarter numbers in recent days.

Here's a booster for my May Dynavax Technologies trade.

The latest quarterly reports indicate consumers are struggling but still are willing to pay for their medicines.

The consumer advocacy group has uncovered discounts of up to 9% off MSRP on these 10 car and SUV models—but you have to act fast.

The 40-year Wall Street veteran looks beyond the tech sector to make his choice of favorite stock for 2025.

Markets could reset Federal Reserve interest rate cut bets following a surprise December inflation report.